NeuroMetrix, Inc. announced that Quell technology will be used in a double-blinded, randomized, sham-controlled trial to determine whether transcutaneous electrical nerve stimulation (TENS) is an effective, acceptable and feasible method of pain relief in patients with NMOSD. The principal investigator is Michael Levy, M.D., Ph.D., Director, NMO Clinic and Research Laboratory, Massachusetts General Hospital, Boston, MA. TENS is a safe, non-pharmacologic pain relief approach. It has been shown to be effective in some forms of neuropathic pain, but has not been extensively evaluated for NMOSD. Quell technology is an advanced TENS platform that is enabled by a proprietary neurostimulation microchip that provides flexible, precise, high-power nerve stimulation in small wearable devices. Quell supports Bluetooth® low energy (BLE) to communicate with mobile applications. The trial will use a modified Quell device and mobile app that allow for an alternative electrode placement and stimulation pattern. The same system is being used in a large, NIH-funded pragmatic clinical trial of TENS for fibromyalgia. The current trial will enroll 46 patients with NMOSD. The subjects will be randomized to an active or sham Quell device for 4 weeks. All subjects will then proceed into a 4-week open-label active treatment phase. The primary outcome measure is the baseline to 4-week change in pain intensity using the 11-point numerical pain scale.